The increasing prevalence of chronic diseases and the rising demand for personalized medicine are key drivers fueling the growth of the recombinant antibodies market. Additionally, advancements in biotechnology and an expanding geriatric population are contributing to the market's growth.
Industry
Report Coverage | Details |
---|---|
Segments Covered | Type, Application |
Regions Covered | • North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA) |
Company Profiled | Abnova, BBI Solutions, F. Hoffmann-La Roche, BIOLEGEND, BD Biosciences, Creative Biolabs, Merck KGaA, Bio-Rad Laboratories, Abcam, SinoBiological, GE Healthcare, ProMab Biotechnologies, Beckman Coulter |
The stringent regulations and high costs associated with research and development are major restraints hindering the growth of the recombinant antibodies market. Furthermore, the complexity of manufacturing processes and the potential risks associated with antibody therapies pose challenges to market expansion.